Expertise in
7
conditions

Russell S. Scott

Christchurch, CAN, NZ 
Expertise in
7
conditions
Christchurch, CAN, NZ 

Overview

Russell Scott practices practicing medicine in Christchurch, New Zealand.

Mr. Scott is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Familial Hypertriglyceridemia, High Cholesterol, Type 2 Diabetes (T2D), and Heterozygous Familial Hypercholesterolemia (HeFH).

He is actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Christchurch, CAN, New Zealand
Other Locations
Auckland, AUK, New Zealand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
Enrollment Status: Completed
Publish Date: June 05, 2026
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 3
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
A Randomised Trial to Evaluate the Efficacy on Retinopathy and Safety of Fenofibrate in Adults With Type 1 Diabetes. A Multicentre Double-blind Placebo-controlled Study in Australia and Internationally.
A Randomised Trial to Evaluate the Efficacy on Retinopathy and Safety of Fenofibrate in Adults With Type 1 Diabetes. A Multicentre Double-blind Placebo-controlled Study in Australia and Internationally.
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drug: Fenofibrate
Study Phase: Phase 3
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome
Enrollment Status: Completed
Publish Date: December 24, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
Enrollment Status: Completed
Publish Date: December 24, 2025
Intervention Type: Drug
Study Drug: ARO-ANG3
Study Phase: Phase 1
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

41 Total Publications

Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.
Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.
Journal: The New England journal of medicine
Published: August 28, 2026

Frequently Asked Questions about Russell S. Scott

Is Russell S. Scott a top-rated expert for Familial Hypertriglyceridemia?

MediFind is an objective health platform that identifies experts based on real-world data. Russell S. Scott is classified as an Advanced expert for Familial Hypertriglyceridemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Russell S. Scott participate in research or clinical trials?

Yes. Russell S. Scott has published 41 articles and abstracts on conditions like Familial Hypertriglyceridemia. You can view a list of Russell S. Scott's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Scott's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile